COR vs. VTRS: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at COR and VTRS, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
| Symbol | COR | VTRS |
|---|---|---|
| Company Name | Cencora, Inc. | Viatris Inc. |
| Country | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Health Care Providers & Services | Pharmaceuticals |
| Market Capitalization | 60.45 billion USD | 11.76 billion USD |
| Exchange | NYSE | NasdaqGS |
| Listing Date | April 4, 1995 | March 17, 1980 |
| Security Type | Common Stock | Common Stock |
Historical Performance
This chart compares the performance of COR and VTRS by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | COR | VTRS |
|---|---|---|
| 5-Day Price Return | 4.33% | 1.96% |
| 13-Week Price Return | 5.57% | 10.86% |
| 26-Week Price Return | 13.80% | 10.49% |
| 52-Week Price Return | 38.52% | -14.29% |
| Month-to-Date Return | -0.24% | -6.16% |
| Year-to-Date Return | 38.76% | -20.48% |
| 10-Day Avg. Volume | 2.01M | 12.69M |
| 3-Month Avg. Volume | 1.41M | 11.42M |
| 3-Month Volatility | 24.74% | 30.68% |
| Beta | 0.64 | 0.90 |
Profitability
Return on Equity (TTM)
COR
196.32%
Health Care Providers & Services Industry
- Max
- 24.86%
- Q3
- 15.79%
- Median
- 8.56%
- Q1
- 5.75%
- Min
- -1.64%
COR’s Return on Equity of 196.32% is exceptionally high, placing it well beyond the typical range for the Health Care Providers & Services industry. This demonstrates a superior ability to generate profit from shareholder investments, though it could also be inflated by high financial leverage.
VTRS
-19.92%
Pharmaceuticals Industry
- Max
- 38.59%
- Q3
- 19.84%
- Median
- 11.85%
- Q1
- 5.40%
- Min
- -10.91%
VTRS has a negative Return on Equity of -19.92%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.
Net Profit Margin (TTM)
COR
0.60%
Health Care Providers & Services Industry
- Max
- 11.56%
- Q3
- 5.45%
- Median
- 2.83%
- Q1
- 1.13%
- Min
- -1.71%
Falling into the lower quartile for the Health Care Providers & Services industry, COR’s Net Profit Margin of 0.60% indicates weaker profitability. This means the company retains a smaller portion of each dollar in sales as profit compared to its competitors.
VTRS
-24.57%
Pharmaceuticals Industry
- Max
- 40.67%
- Q3
- 19.07%
- Median
- 12.31%
- Q1
- 4.50%
- Min
- -9.91%
VTRS has a negative Net Profit Margin of -24.57%, indicating the company is operating at a net loss as its expenses exceeded its revenues.
Operating Profit Margin (TTM)
COR
0.85%
Health Care Providers & Services Industry
- Max
- 19.08%
- Q3
- 9.66%
- Median
- 4.77%
- Q1
- 2.46%
- Min
- -0.83%
COR’s Operating Profit Margin of 0.85% is in the lower quartile for the Health Care Providers & Services industry. This indicates weaker profitability from core operations, which may stem from inefficiencies or competitive pressures on pricing.
VTRS
-26.54%
Pharmaceuticals Industry
- Max
- 45.78%
- Q3
- 23.14%
- Median
- 16.68%
- Q1
- 7.98%
- Min
- -7.13%
VTRS has a negative Operating Profit Margin of -26.54%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.
Profitability at a Glance
| Symbol | COR | VTRS |
|---|---|---|
| Return on Equity (TTM) | 196.32% | -19.92% |
| Return on Assets (TTM) | 2.70% | -8.50% |
| Net Profit Margin (TTM) | 0.60% | -24.57% |
| Operating Profit Margin (TTM) | 0.85% | -26.54% |
| Gross Profit Margin (TTM) | 3.40% | 40.15% |
Financial Strength
Current Ratio (MRQ)
COR
0.90
Health Care Providers & Services Industry
- Max
- 2.00
- Q3
- 1.51
- Median
- 1.29
- Q1
- 0.92
- Min
- 0.14
COR’s Current Ratio of 0.90 falls into the lower quartile for the Health Care Providers & Services industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
VTRS
1.37
Pharmaceuticals Industry
- Max
- 4.65
- Q3
- 2.64
- Median
- 1.85
- Q1
- 1.26
- Min
- 0.78
VTRS’s Current Ratio of 1.37 aligns with the median group of the Pharmaceuticals industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio (MRQ)
COR
4.16
Health Care Providers & Services Industry
- Max
- 2.29
- Q3
- 1.24
- Median
- 0.74
- Q1
- 0.50
- Min
- 0.00
With a Debt-to-Equity Ratio of 4.16, COR operates with exceptionally high leverage compared to the Health Care Providers & Services industry norm. This suggests an aggressive reliance on debt financing, which can magnify returns but also significantly elevates financial risk.
VTRS
0.82
Pharmaceuticals Industry
- Max
- 1.75
- Q3
- 0.82
- Median
- 0.35
- Q1
- 0.13
- Min
- 0.00
VTRS’s leverage is in the upper quartile of the Pharmaceuticals industry, with a Debt-to-Equity Ratio of 0.82. While this approach can boost equity growth, it also exposes the company to greater financial vulnerability.
Interest Coverage Ratio (TTM)
COR
13.67
Health Care Providers & Services Industry
- Max
- 14.47
- Q3
- 7.50
- Median
- 4.52
- Q1
- 2.12
- Min
- -4.44
COR’s Interest Coverage Ratio of 13.67 is in the upper quartile for the Health Care Providers & Services industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.
VTRS
-0.13
Pharmaceuticals Industry
- Max
- 103.95
- Q3
- 43.60
- Median
- 9.83
- Q1
- 2.37
- Min
- -42.71
VTRS has a negative Interest Coverage Ratio of -0.13. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.
Financial Strength at a Glance
| Symbol | COR | VTRS |
|---|---|---|
| Current Ratio (MRQ) | 0.90 | 1.37 |
| Quick Ratio (MRQ) | 0.52 | 0.65 |
| Debt-to-Equity Ratio (MRQ) | 4.16 | 0.82 |
| Interest Coverage Ratio (TTM) | 13.67 | -0.13 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
COR
0.71%
Health Care Providers & Services Industry
- Max
- 5.93%
- Q3
- 2.59%
- Median
- 1.35%
- Q1
- 0.00%
- Min
- 0.00%
COR’s Dividend Yield of 0.71% is consistent with its peers in the Health Care Providers & Services industry, providing a dividend return that is standard for its sector.
VTRS
4.84%
Pharmaceuticals Industry
- Max
- 7.14%
- Q3
- 3.45%
- Median
- 2.17%
- Q1
- 0.33%
- Min
- 0.00%
With a Dividend Yield of 4.84%, VTRS offers a more attractive income stream than most of its peers in the Pharmaceuticals industry, signaling a strong commitment to shareholder returns.
Dividend Payout Ratio (TTM)
COR
22.69%
Health Care Providers & Services Industry
- Max
- 185.33%
- Q3
- 74.82%
- Median
- 36.00%
- Q1
- 0.00%
- Min
- 0.00%
COR’s Dividend Payout Ratio of 22.69% is within the typical range for the Health Care Providers & Services industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
VTRS
137.04%
Pharmaceuticals Industry
- Max
- 199.58%
- Q3
- 97.17%
- Median
- 53.47%
- Q1
- 22.97%
- Min
- 0.00%
VTRS’s Dividend Payout Ratio of 137.04% is in the upper quartile for the Pharmaceuticals industry. This indicates a strong commitment to shareholder returns but also suggests that a smaller portion of earnings is retained for reinvestment compared to many peers.
Dividend at a Glance
| Symbol | COR | VTRS |
|---|---|---|
| Dividend Yield (TTM) | 0.71% | 4.84% |
| Dividend Payout Ratio (TTM) | 22.69% | 137.04% |
Valuation
Price-to-Earnings Ratio (TTM)
COR
32.02
Health Care Providers & Services Industry
- Max
- 40.02
- Q3
- 29.75
- Median
- 21.09
- Q1
- 14.18
- Min
- 7.05
A P/E Ratio of 32.02 places COR in the upper quartile for the Health Care Providers & Services industry. This high valuation relative to peers suggests the market holds elevated expectations for the company’s future growth.
VTRS
--
Pharmaceuticals Industry
- Max
- 45.19
- Q3
- 27.91
- Median
- 20.59
- Q1
- 15.08
- Min
- 3.79
P/E Ratio data for VTRS is currently unavailable.
Price-to-Sales Ratio (TTM)
COR
0.19
Health Care Providers & Services Industry
- Max
- 3.15
- Q3
- 1.87
- Median
- 0.74
- Q1
- 0.27
- Min
- 0.09
In the lower quartile for the Health Care Providers & Services industry, COR’s P/S Ratio of 0.19 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.
VTRS
0.83
Pharmaceuticals Industry
- Max
- 8.87
- Q3
- 4.56
- Median
- 2.14
- Q1
- 1.58
- Min
- 0.11
In the lower quartile for the Pharmaceuticals industry, VTRS’s P/S Ratio of 0.83 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.
Price-to-Book Ratio (MRQ)
COR
29.35
Health Care Providers & Services Industry
- Max
- 7.33
- Q3
- 4.45
- Median
- 2.52
- Q1
- 1.15
- Min
- 0.66
At 29.35, COR’s P/B Ratio is at an extreme premium to the Health Care Providers & Services industry. This signifies that the market’s valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.
VTRS
0.67
Pharmaceuticals Industry
- Max
- 9.78
- Q3
- 4.99
- Median
- 2.48
- Q1
- 1.53
- Min
- 0.59
VTRS’s P/B Ratio of 0.67 is in the lower quartile for the Pharmaceuticals industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.
Valuation at a Glance
| Symbol | COR | VTRS |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 32.02 | -- |
| Price-to-Sales Ratio (TTM) | 0.19 | 0.83 |
| Price-to-Book Ratio (MRQ) | 29.35 | 0.67 |
| Price-to-Free Cash Flow Ratio (TTM) | 9.49 | 6.89 |